PACTR202008567047887
Recruiting
Phase 3
Evaluation of neuroprotective effect of dexmedetomidine in patients undergoing brain tumor resection?
Mona Raafat Elghamry0 sites40 target enrollmentMay 16, 2020
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Mona Raafat Elghamry
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients aged 20\-60 years,
- •ASA class I and II,
- •who undergo elective supratentorial tumor resection surgery
Exclusion Criteria
- •patient's refusal,
- •pre\-existing psychiatric disorders or cognitive dysfunction,
- •cerebral infarction,
- •frontal lesions
- •A\-V heart block,
- •patients who need intraoperative blood transfusion or those who need postoperative mechanical ventilation
- •surgery in prone position.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Cardio protective effect of dexmedetomidine in CABGmyocardial injury.Other functional disturbances following cardiac surgeryIRCT2016071113456N6Vice chancellor for research of Guilan University of Medical Sciences110
Active, not recruiting
Not Applicable
Role of brain protection drug in epilepsy surgeryHealth Condition 1: null- Patients Undergoing Epilepsy SurgeryCTRI/2016/10/007406ALL INDIA INSTITUTE OF MEDICAL SCIENCES20
Recruiting
Phase 3
Comparision of Dexmedetomidine and Fentanyl in pain control.IRCT20200613047760N1Ahvaz University of Medical Sciences56
Completed
Not Applicable
The protective effect of dexmedetomidine against acute kidney injury in sepsisAcute kidney injury in sepsis.acute kidney injury, sepsis, dexmedetomidineTCTR20230925003/A331
Completed
Phase 3
Dexmedetomidine in rhinoplastyIRCT20211225053519N3Tehran University of Medical Sciences42